Clinical Trial

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-06-01; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-10-16
Trial Details
NCT Number NCT07011654
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Y-mAbs Therapeutics
Conditions Metastatic Triple-Negative Breast Cancer
Enrollment 31 participants
Start Date 2025-09-19
Primary Completion 2028-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-07